Compare Summit Therapeutics Inc (SMMT) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Summit Therapeutics Inc trades at $15.1 (market cap $12.06B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $59.13. The key difference: SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | SPUS | |
|---|---|---|
Market Cap | $12.06B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $26.98 | $59.51 |
52-Week Low | $12.55 | $46.28 |
Enterprise Value | $11.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
SPUS trades at $59.11, up 0.27% today, with technical indicators showing a bullish trend supported by moving averages. The stock exhibits strong momentum with key indicators favoring upside potential. Recent dividend distributions of $0.03 per share in H1-26 demonstrate shareholder returns, though key valuation metrics remain undisclosed in current data.
The outlook remains positive given technical strength and dividend consistency, though limited fundamental data availability warrants caution. Key risks include market volatility and potential overbought conditions indicated by short-term RSI levels. Investors should monitor upcoming earnings for fundamental validation of current technical optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
